Human Immunodeficiency Virus Book

http://www.fpnotebook.com/

AbacavirAka: Ziagen

Advertisement

  1. Mechanism
    1. Nucleoside Reverse Transcriptase Inhibitor
  2. Dosing
    1. Abacavir 300 mg PO bid
  3. Precautions
    1. Do not use in Asian patients unless they are negative for HLA-B1502
      1. Risk of Steven's Johnson: 5% if HLA-B1502 positive
      2. (2007) J Antimicrob Chemother 59(4):591
  4. Adverse Effects
    1. Hypersensitivity (3%)
      1. Mean onset 11 days after start
      2. Lethal reaction if restarted after reaction (50%)
      3. Never rechallenge Abacavir after reaction
  5. Resources: Abacavir Hypersensitivity Registry
    1. Phone: 1-800-270-0425
  6. Reference
    1. Med Lett Drugs Ther (1998) 40(1041):115

abacavir (C0663655)

Definition (NCI)A synthetic carbocyclic nucleoside analog. In vivo, the activated triphosphate metabolite of abacavir is incorporated into the viral DNA instead of the natural substrate deoxyguanosine, thereby inhibiting human immunodeficiency virus (HIV) reverse transcriptase (RT) and, so, the replication of the viral DNA and infectious viral particles. This agent decreases HIV viral loads, retards or prevents the damage to the immune system, and reduces the risk of developing AIDS.
Definition (CSP)carbocyclic nucleoside with anti-HIV activity.
ConceptsNucleic Acid, Nucleoside, or Nucleotide (T114) , Pharmacologic Substance (T121)
MSHC106538
Englishabacavir, Abacavir - chemical, ABACAVIR PREPARATION
Spanishabacavir
Parent ConceptsAntiviral Agents (C0003451), Deoxyribonucleosides (C0011528), Reverse Transcriptase Inhibitors (C0282519), 1592U89 (C0540137), Retroviral protease inhibitor (C1268897), Abacavir or derivative (C1445626), Duplicate concept (C1274013), Anti-HIV Agents, Nucleoside and Nucleotide Reverse Transcriptase Inhibitors (C1579421)
SourcesCSP, LNC, MSH, MTH, NCI, NDFRT, RXNORM, SCTSPA, SNOMEDCT, USPMG, VANDF
Derived from the NIH UMLS (Unified Medical Language System)


Ziagen (C0724476)

ConceptsNucleic Acid, Nucleoside, or Nucleotide (T114) , Pharmacologic Substance (T121)
MSHC106538
EnglishZiagen
SourcesMSH, NCI, RXNORM
Derived from the NIH UMLS (Unified Medical Language System)



Navigation Tree